T3P-Y058-1
Solid Tumors
Key Facts
About T3 Pharmaceuticals
T3 Pharmaceuticals is a private, pre-revenue biotech pioneering a novel bacterial cancer therapy platform. Leveraging a proprietary Type 3 Secretion System (T3SS) technology, the company engineers non-pathogenic bacteria to selectively invade solid tumors and deliver immunomodulatory or cytotoxic payloads directly into cancer cells. With a seasoned leadership team combining deep scientific expertise in microbiology and immunology with extensive clinical development experience from major pharma, T3 is positioned to advance a new class of targeted oncolytic agents. The company is headquartered in the Basel life sciences hub and is supported by a board and advisory network with strong ties to Boehringer Ingelheim and leading academic institutions.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |